... Food and Drug Administration Elrexfio (Elranatamab-Bcmm), Prescribing Information Revised July 2025 — U.S. Food and Drug Administration FDA Approves Teclistamab-Cqyv for Relapsed or Refractory Multiple Myeloma — U.S. Food and Drug Administration FDA Grants Accelerated Approval to Elrantamab-Bcmm for Multiple Myeloma — U.S. ...
What Is BCMA-Targeted Immunotherapy? (VIDEO)
... Food and Drug Administration Elrexfio (Elranatamab-Bcmm), Prescribing Information Revised July 2025 — U.S. Food and Drug Administration FDA Approves Teclistamab-Cqyv for Relapsed or Refractory Multiple Myeloma — U.S. Food and Drug Administration FDA Grants Accelerated Approval to Elrantamab-Bcmm for Multiple Myeloma — U.S. ...
... Food and Drug Administration FDA Grants Accelerated Approval to Elranatamab-Bcmm for Multiple Myeloma — U.S. Food and Drug Administration FDA Grants Accelerated Approval to Linvoseltamab-Gcpt for Relapsed or Refractory Multiple Myeloma — U.S. ...
What Is the Life Expectancy With Relapsed/Refractory Myeloma?
... Food and Drug Administration FDA Grants Accelerated Approval to Elranatamab-Bcmm for Multiple Myeloma — U.S. Food and Drug Administration FDA Grants Accelerated Approval to Linvoseltamab-Gcpt for Relapsed or Refractory Multiple Myeloma — U.S. ...
... PFS refers to the time until cancer starts growing, and OS is how long people live after starting treatment.Elranatamab-Bcmm Results ORR — 57.7 percent About half of responders had a complete response (all signs of cancer disappeared). About 82 percent of responders were still in response after nine months of treatment. ...
Bispecific T-Cell Engagers for RRMM: 6 Facts About a New Type of Treatment
... PFS refers to the time until cancer starts growing, and OS is how long people live after starting treatment.Elranatamab-Bcmm Results ORR — 57.7 percent About half of responders had a complete response (all signs of cancer disappeared). About 82 percent of responders were still in response after nine months of treatment. ...
... Elranatamab-bcmm (Elrexfio) is another BCMA-directed CD3 T-cell engager. Talquetamab-tgvs (Talvey) is a bispecific T-cell engager that targets GPRC5D, another protein found on myeloma cells, and CD3 on T cells. Selinexor (Xpovio) is a nuclear export inhibitor that disrupts how cancer cells function and grow. ...
Relapsed vs. Refractory: What It Means in Multiple Myeloma
... Elranatamab-bcmm (Elrexfio) is another BCMA-directed CD3 T-cell engager. Talquetamab-tgvs (Talvey) is a bispecific T-cell engager that targets GPRC5D, another protein found on myeloma cells, and CD3 on T cells. Selinexor (Xpovio) is a nuclear export inhibitor that disrupts how cancer cells function and grow. ...
... These treatments can also cause CRS and other side effects, so close monitoring is necessary during the first few doses.Bispecific antibodies used to treat myeloma include: Elranatamab-bcmm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab-tgvs (Talvey) Teclistamab-cqyv (Tecvayli) Antibody-Drug ConjugateAnother immunotherapy your doctor may recommend ...
Myeloma Treatment Journey: From First Line to Fourth Line
... These treatments can also cause CRS and other side effects, so close monitoring is necessary during the first few doses.Bispecific antibodies used to treat myeloma include: Elranatamab-bcmm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab-tgvs (Talvey) Teclistamab-cqyv (Tecvayli) Antibody-Drug ConjugateAnother immunotherapy your doctor may recommend ...
... refractory multiple myeloma.In 2019, the FDA approved selinexor (Xpovio), offering a new mechanism of action as a selective inhibitor of nuclear export.The approval of isatuximab-irfc (Sarclisa) in 2020, along with newer bispecific T-cell engagers like teclistamab-cqyv (Tecvayli, approved in 2022), as well as talquetamab-tgvs (Talvey) and elranatamab-bcmm ...
Multiple Myeloma – An Overview
... refractory multiple myeloma.In 2019, the FDA approved selinexor (Xpovio), offering a new mechanism of action as a selective inhibitor of nuclear export.The approval of isatuximab-irfc (Sarclisa) in 2020, along with newer bispecific T-cell engagers like teclistamab-cqyv (Tecvayli, approved in 2022), as well as talquetamab-tgvs (Talvey) and elranatamab-bcmm ...
... Elranatamab-bcmm, sold under the brand name Elrexfio, is a BCMA bispecific antibody approved by the FDA in August 2023.7. CAR T-Cell TherapiesTwo BCMA-targeted antibodies are used in a type of treatment known as chimeric antigen receptor (CAR) T-cell therapy, which involves teaching the immune system’s T cells to attack myeloma cells. ...
Myeloma Relapse Rates and 9 Treatment Options for Relapses
... Elranatamab-bcmm, sold under the brand name Elrexfio, is a BCMA bispecific antibody approved by the FDA in August 2023.7. CAR T-Cell TherapiesTwo BCMA-targeted antibodies are used in a type of treatment known as chimeric antigen receptor (CAR) T-cell therapy, which involves teaching the immune system’s T cells to attack myeloma cells. ...
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
Myeloma Treatments: Risks and Benefits
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
... As a result, teclistamab-cqyv causes tumor-cell lysis (destruction).Other bispecific T-cell engagers sometimes used to treat myeloma are talquetamab-tgvs (Talvey), elranatamab-bcmm (Elrexfio), and linvoseltamab-gcpt (Lynozyfic).6. Targeted TherapiesTargeted therapies limit how much cancer cells can divide, multiply, and spread. ...
12 Myeloma Treatment Options
... As a result, teclistamab-cqyv causes tumor-cell lysis (destruction).Other bispecific T-cell engagers sometimes used to treat myeloma are talquetamab-tgvs (Talvey), elranatamab-bcmm (Elrexfio), and linvoseltamab-gcpt (Lynozyfic).6. Targeted TherapiesTargeted therapies limit how much cancer cells can divide, multiply, and spread. ...
Join
Your Privacy Choices
